A phase II study of decitabine and carboplatin in recurrent platinum (Pt)-resistant ovarian cancer (OC).

Daniela Matei,Changyu Shen,Fang Fang,Jeanne M. Schilder,Meng Li,A. Arnold,Yan Zeng,Jay Pilrose,C. Kulesavage,Curt Balch,William A. Berry,P. Wulfridge,Tim H-M Huang,Kenneth P. Nephew

A phase II study of decitabine and carboplatin in recurrent platinum (Pt)-resistant ovarian cancer (OC).

2011

Daniela Matei
Changyu Shen
Fang Fang
Jeanne M. Schilder
Meng Li
A. Arnold
Yan Zeng
Jay Pilrose
C. Kulesavage
Curt Balch
William A. Berry
P. Wulfridge
Tim H-M Huang
Kenneth P. Nephew

5011 Background: Aberrant DNA methylation is a hallmark of cancer. Preclinical studies showed that hypomethylating agents reverse Pt resistance, supporting testing low dose decitabine (D) combined ...

Keywords:

Carboplatin
Ovarian cancer
Physical therapy
Cancer research
Decitabine
Platinum
Medicine
Aberrant DNA Methylation
Cancer
Pathology
low dose
Phases of clinical research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations